Evolving Gene Therapy: A Deep Dive into 3rd-Generation Lentiviral Vectors Clinician's Roundtable

Host: Matt Birnholz, MD

Guest: Donald Kohn, MD



Third-generation lentiviral vectors were developed to improve upon safety measures and mitigate the risks of toxicity and replication that are typically associated with first- and second-generation therapies. These advancements may help enhance the functionality and utility of third-generation lentiviral vectors in various gene therapy applications. Learn more about the development, efficacy, and safety of third-generation lentiviral vectors with Dr. Matt Birnholz and Dr. Donald Kohn, Distinguished Professor at the University of California, Los Angeles.
This non-certified educational series is produced and controlled by ReachMD, and is intended for healthcare professionals only.